Would you switch to TDM-1 in the adjuvant setting in HER-2 positive breast cancer patients with residual disease after neoadjuvant chemotherapy if neoadjuvant chemotherapy did not include anthracyclines?

The introduction of dual HER2 blockade has significantly increased the pathologic complete response rate of HER2+ disease to neoadjuvant therapy. The TRAIN-2 trial demonstrated that anthracycline based therapy did not increase the PCR rate over a taxane based regimen when dual blockade was used. APH...